(GLOBE NEWSWIRE)-- 23andMe Research Institute, a nonprofit medical research organization, today announced the formation of ...

Ho's appointment adds more than 20 years of oncology, biopharma and capital markets experience, including senior roles in ...

Interim findings highlight ECM hydrogel’s potential for patients with limited treatment options. WARRENDALE, Pa., Oct. 13, ...

Evergreen Therapeutics, Inc., a Maryland based clinical-stage biotechnology company leveraging artificial intelligence (AI) ...

Abram Scientific, a medical device company focused on advancing next-generation coagulation diagnostics, today announced that ...

Next-generation posterior cervical implant pairs 3D-printed porous titanium with the clinically proven CORUS™ PCSS design.

This marks the first new treatment approved for IPF in Canada in over a decade and for PPF in more than five years. 1, 2 ...

Round of more than $6 million, led by Colle Capital Partners with support from Orlando Health Ventures, will fund completion ...

Randomized, placebo-controlled study in 16 cognitively unimpaired participants met safety and immunogenicity objectives; all ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of the ...

(NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, said ...

Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company ...